Related Experiment Video
Updated: Aug 26, 2026

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments
Published on: May 9, 2019
Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse
1Department of Orthopaedic Surgery, Carolinas Medical Center, P.O. Box 32861, Charlotte, NC 28232, USA. hgruber@carolinas.org
Abstract:
In the present study, we used osteoprotegerin (OPG), which blocks osteoclastogenesis, to correct and thus explain the hypercalcemia that is seen during dietary Mg deficiency in the mouse. Control and Mg-deficient mice received injections for 12 days of either OPG or vehicle only. Serum Ca was similar in Mg-deficient mice treated with OPG and in control mice receiving OPG (9.2 +/- 0.3 mg/dl vs. 9.2 +/- 0.5). Both groups had significantly higher serum Ca than controls or Mg-deficient animals receiving vehicle alone. Surprisingly, Mg-depleted mice that received OPG in doses that inhibit osteoclastic bone resorption remained hypercalcemic. Because mature osteoclasts still present in the marrow might be hyperactive, we examined osteoclast morphology at the light microscopic and ultrastructural level. Light microscopic examination of trabecular bone showed few osteoclasts in OPG-treated mice. Ultrastructural examination revealed that osteoclasts in OPG-treated mice have decreased contact with the endosteal bone surface and absence of a ruffled border. Because the morphology of the existing pool of mature osteoclasts did not enhance resorption, another mechanism, such as increased intestinal absorption of Ca in Mg-deficient mice, likely contributes to the hypercalcemia observed during Mg deficiency.
Insights
Osteoprotegerin (OPG) treatment did not resolve hypercalcemia in magnesium-deficient mice. This suggests increased intestinal calcium absorption, not bone resorption, drives high calcium levels during Mg deficiency.
Area of Science:
- Biochemistry
- Physiology
- Endocrinology
Background:
- Dietary magnesium deficiency in mice causes hypercalcemia.
- Osteoprotegerin (OPG) is known to inhibit osteoclastogenesis and bone resorption.
Purpose of the Study:
- To investigate the role of osteoclastogenesis in hypercalcemia associated with magnesium deficiency.
- To determine if OPG can correct hypercalcemia in magnesium-deficient mice.
Main Methods:
- Mice were fed a magnesium-deficient diet or a control diet.
- Mice received daily injections of OPG or vehicle for 12 days.
- Serum calcium levels were measured.
- Osteoclast morphology was examined using light and electron microscopy.
Main Results:
- OPG treatment did not correct hypercalcemia in magnesium-deficient mice.
- Serum calcium levels were elevated in both OPG-treated magnesium-deficient mice and OPG-treated control mice compared to vehicle-treated groups.
- Ultrastructural examination revealed osteoclasts with reduced bone contact and absent ruffled borders in OPG-treated mice.
Conclusions:
- Hypercalcemia in magnesium deficiency is not solely mediated by osteoclastic bone resorption.
- Increased intestinal calcium absorption likely contributes to hypercalcemia during magnesium deficiency.
- OPG's inhibition of osteoclast activity does not resolve hypercalcemia in this model.
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
